Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.

ABSTRACT:

Background

Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments.

Methods

We performed a systematic review to evaluate the monthly risk of grade III/IV infection, pneumonia, and neutropenia in patients with myeloma enrolled in randomized clinical trials (RCTs).

Results

The risk of grade III or higher infection, pneumonia, and neutropenia persists among all phases of treatment. There was no statistical difference in grade III or higher infection, pneumonia, and neutropenia between frontline and relapsed/refractory setting. In the maintenance setting, the complications of infection, pneumonia, and neutropenia were low, but not negligible. Three-drug regimens were no more likely than two

SUBMITTER: Balmaceda N 

PROVIDER: S-EPMC8233183 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature